Minocycline foam - Foamix

Drug Profile

Minocycline foam - Foamix

Alternative Names: FMX 101; FMX 102; FMX 103; FXFM-244

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Foamix
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Glial cell inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris; Rosacea
  • Phase II Impetigo

Most Recent Events

  • 01 Sep 2017 Foamix initiates enrolment in a phase III trial for Rosacea in USA (NCT03276936)
  • 03 Aug 2017 Foamix initiates enrolment in a phase III trial for Acne in USA (Study FX2017-22)
  • 03 Aug 2017 Foamix intends to complete an open-label safety extension of FMX 101 from phase III trials (Study 04 and Study 05)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top